Vimarsana
Biggest News Aggregation in the World

Page 4 - Veronica Eames News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Veronica Eames. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Veronica Eames Today - Breaking & Trending Today

Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1) - Vimarsana News

Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1)

The opinion was based on positive results from the pivotal ReSTORE Phase III clinical trial and supported by the STRIVE Phase II clinical trials and extensive nonclinical development program.2,3If...

Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009 - Vimarsana News

Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009

- Phase 2a NASH protocol on track to be submitted to the IND in Q4 2023, enrollment expected to begin in Q1 2024SOUTH SAN FRANCISCO, Calif., Sept. 21, 2023 -- Aligos Therapeutics, Inc. , a clinical...

Cidara Therapeutics Provides Update on Status of Ongoing CD388 Influenza Program - Vimarsana News

Cidara Therapeutics Provides Update on Status of Ongoing CD388 Influenza Program

SAN DIEGO, July 20, 2023 -- Cidara Therapeutics, Inc. , a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious...

Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023 - Aligos Therapeutics (NASDAQ:ALGS) - Vimarsana News

Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023 - Aligos Therapeutics (NASDAQ:ALGS)

-Presentations include a late breaking poster from an ongoing Phase 1b study of ALG-000184 demonstrating multi-log reductions in HBsAg, DNA, and RNA levels in subjects dosed for up to 36 weeks- -Data collectively

Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023 - Vimarsana News

Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023

-Presentations include a late breaking poster from an ongoing Phase 1b study of ALG-000184 demonstrating multi-log reductions in HBsAg, DNA, and RNA levels in subjects dosed for up to 36 weeks- -Data collectively highlight company’s progress advanc...